Adjuvant chemotherapy for colorectal hepatic metastases: role of route of administration and timing.

Journal Article

Improved results in the adjuvant and therapeutic treatment of colon cancer has led to renewed interest in the role of adjuvant chemotherapy following liver resection for colorectal hepatic metastases. However, little is known about the most effective method or timing of delivery of adjuvant chemotherapy. Sixty-nine BD-IX rats underwent a right hepatic lobectomy following tumour inoculation via a splenic injection of 10(7) K12/TRb colon cancer cells. The rats were then randomized to receive systemic FUdR (1 mg kg-1 d-1 for 7 d) or regional (hepatic artery or portal vein) FUdR (2 mg kg-1 d-1 for 7 d) immediately or 72 h following tumour injection. On Day 28, a laprotomy was performed, and tumour nodules in the liver were counted. The animals were followed to death, and at autopsy the cause of death from hepatic or extrahepatic metastases was determined. All methods of FUdR infusion were superior to no treatment. Immediate portal vein (PV) FUdR infusion delayed the appearance of hepatic tumour (P = 0.003), changed the cause of death from hepatic to extrahepatic disease (P = 0.019), and prolonged survival (P < 0.05). Infusion of FUdR via the PV 72 h later did not delay the appearance of hepatic tumours nor prolong survival. In contrast, delayed HA FUdR infusion controlled hepatic metastases (P = 0.04) and improved survival (P < 0.05).

Full Text

Duke Authors

Cited Authors

  • Sutanto-Ward, E; Sigurdson, ER; Tremiterra, S; Lincer, R; Chapman, D; Niedzwiecki, D

Published Date

  • February 1, 1992

Published In

Volume / Issue

  • 1 / 1

Start / End Page

  • 87 - 95

PubMed ID

  • 1341240

International Standard Serial Number (ISSN)

  • 0960-7404

Language

  • eng

Conference Location

  • Netherlands